MedImmune, Inc. Forms New Cancer Research Partnership

BOSTON, Dec 8 (Reuters) - MedImmune Inc. (MEDI.O: Quote, Profile, Research) said on Thursday it has formed a new partnership to expand its line of cancer treatments. The Gaithersburg, Maryland-based biotechnology company signed an agreement with the not-for-profit Burnham Institute for Medical Research to develop drugs targeting a family of proteins known as EphA and EphB, which are believed to play a role in uncontrolled tumor growth in many cancers.

Back to news